Acceder Registro /

GINES LUENGO GIL

Buscador

Garcia-Torralba E, Navarro Manzano E, Luengo-Gil G, De la Morena Barrio P, Chaves Benito A, Perez-Ramos M, Alvarez-Abril B, Ivars Rubio A, Garcia-Garre E, Ayala de la Pena F, Garcia-Martinez E. A new prognostic model including immune biomarkers, genomic proliferation tumor markers (AURKA and MYBL2) and clinical-pathological features optimizes prognosis in neoadjuvant breast cancer patients. Front Oncol. 2023 May 29;13:1182725. doi: 10.3389/fonc.2023.1182725. eCollection 2023. PubMed PMID: 37313470; PubMed Central PMCID: PMC10258327.
AÑO: 2023; IF: 4.7
Rodenas MC, Penas-Martinez J, Pardo-Sanchez I, Zaragoza-Huesca D, Ortega-Sabater C, Pena-Garcia J, Espin S, Ricote G, Montenegro S, Ayala-De La Pena F, Luengo-Gil G, Nieto A, Garcia-Molina F, Vicente V, Bernardi F, Lozano ML, Mulero V, Perez-Sanchez H, Carmona-Bayonas A, Martinez-Martinez I. Venetoclax is a potent hepsin inhibitor that reduces the metastatic and prothrombotic phenotypes of hepsin-expressing colorectal cancer cells. Front Mol Biosci. 2023 May 19;10:1182925. doi: 10.3389/fmolb.2023.1182925. eCollection 2023. PubMed PMID: 37275957; PubMed Central PMCID: PMC10235687.
AÑO: 2023; IF: 5.0
Asensi-Cantó A, López-Abellán MD, Castillo-Guardiola V, Hurtado AM, Martínez-Penella M, Luengo-Gil G, Conesa-Zamora P. Antitumoral Effects of Tricyclic Antidepressants: Beyond Neuropathic Pain Treatment. Cancers (Basel). 2022 Jul 1;14(13). pii: 3248. doi: 10.3390/cancers14133248. Review. PubMed PMID: 35805019.
AÑO: 2022; IF: 6.575
Alburquerque-González B, López-Abellán MD, Luengo-Gil G, Montoro-García S, Conesa-Zamora P. Design of Personalized Neoantigen RNA Vaccines Against Cancer Based on Next-Generation Sequencing Data. Methods Mol Biol. 2022;2547:165-185. doi: 10.1007/978-1-0716-2573-6_7. PubMed PMID: 36068464.
AÑO: 2022
de Alarcón R, Alburquerque-González B, Fernández-Valera Á, Molina-Nuñez M, Álvarez Fernandez G, Consuegra-Sánchez L, Luengo-Gil G, Conesa-Zamora P. Pharmacogenetic role of vitamin D-binding protein and vitamin D receptor polymorphisms in the treatment response of dialysis patients with secondary hyperparathyroidism. Nephrol Dial Transplant. 2022 Mar 25;37(4):792-795. doi: 10.1093/ndt/gfab353. PubMed PMID: 34888693.
AÑO: 2022; IF: 6.1

Instituto de Investigación Sanitaria Acreditado

ISCII

Fondo Social Europeo "El FSE Invierte en tu futuro"

Fondo Social Europeo

Sello de Calidad Europeo "HR Excellence in Research"

HRS4R